CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

The Food and Drug Administration as approved the first generic of a drug used to treat severe hypoglycemia. The agency has approved a generic glucagon for injection, 1 mg, from Amphastar ...

The FDA has approved the first generic equivalent of Glucagon Emergency Kit (Lilly), according to Amphastar Pharmaceuticals. Amphastar Pharmaceuticals announced that the Food and Drug Administration ...

Xeris Pharmaceuticals has opened another front in its fight to win market share from Eli Lilly and Novo Nordisk with the FDA approval of its Gvoke Kit for the treatment of severe hypoglycemia. Chicago ...

DANBURY, Conn., June 6, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (BIOD) today announced plans to submit a New Drug Application (NDA) to the FDA in 2015 for a novel glucagon rescue device to treat severe ...

Austin, TX's Xeris Pharmaceuticals wrapped up a $41 million Series C financing round, as it heads toward approval (or rejection) of its diabetes injection pen for the administration of glucagon, a ...

The use of affected product may fail to treat patients with severe hypoglycemia due to a loss of potency. Eli Lilly is voluntarily recalling 1 lot of Glucagon ® Emergency Kit for Low Blood Sugar to ...

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the availability in the United States of its Glucagon Emergency Kit, an FDA-approved and cost-effective alternative to treat severe ...